Skip to content

Cardiac rehabilitation and lifestyle

TL;DR — Exercise-based cardiac rehabilitation (CR) is a secondary-prevention treatment, not an optional wellness add-on. An 85-trial meta-analysis found cardiovascular mortality RR 0.74 (NNT about 37), fewer hospitalizations, and better quality of life, although all-cause mortality was not significantly reduced and trials were heterogeneous (Dibben 2023, PMID 36746187). Home-based and center-based models produce broadly similar clinical and quality-of-life outcomes in selected patients, so delivery should follow access and preference rather than a single venue (McDonagh 2023, PMID 37888805). Smoking cessation is categorical—cutting down does not remove most cardiovascular risk—while dietary evidence supports Mediterranean-pattern food systems rather than isolated supplements (Chang 2021, PMID 32803250; Estruch 2018, PMID 29897866). The SECURE polypill reduced post-MI MACE (HR 0.76), showing that adherence engineering can itself change outcomes (Castellano 2022, PMID 36018037). The largest gap is uptake: referral, attendance, completion, and maintenance each lose patients.

What comprehensive CR contains

Component Measured target Examples of outputs
Exercise assessment/training Capacity, symptoms, BP/HR response Peak work, walk distance, training minutes
Risk-factor management LDL, BP, glycemia, tobacco Medication optimization and verified cessation
Education Disease and treatment understanding Action plan, adherence, emergency recognition
Nutrition Dietary pattern and energy balance Mediterranean-style pattern, weight trajectory
Psychosocial care Depression, anxiety, cardiac fear, social support Screening, referral, graded return to activity
Vocational/sexual counseling Return to roles Individualized safety and confidence
Long-term transition Maintenance after program Community/home plan and follow-up

Exercise-only trials underestimate the scope of modern comprehensive CR; conversely, multicomponent programs make it difficult to assign outcome effects to one component (Dibben 2021, PMID 34741536).

Outcomes evidence

The 2023 meta-analysis of randomized trials in coronary disease reported cardiovascular mortality RR 0.74 (95% CI 0.64–0.86; NNT 37), hospitalization RR 0.77 (95% CI 0.67–0.89; NNT 37) and myocardial infarction RR 0.82 (95% CI 0.70–0.96; NNT 100) over trial horizons, with improved quality of life (Dibben 2023, PMID 36746187).

Outcome Direction of evidence Qualification
Cardiovascular mortality Reduced Trials span decades and treatment eras
All-cause mortality No clear reduction Competing deaths and power matter
Hospitalization Reduced Definitions and follow-up differ
Quality of life Improved Instruments heterogeneous
Recurrent MI Uncertain/smaller effect Modern event rates lower
Exercise capacity Improved Strongly influenced by training dose/adherence

Earlier Cochrane syntheses reached similar conclusions but emphasized risk of bias and changing background therapy (Anderson 2016, PMID 26764059; Dibben 2021, PMID 34741536).

Center, home, and hybrid delivery

Home-based and center-based CR show similar outcomes in selected trial participants, supporting patient choice and hybrid delivery (McDonagh 2023, PMID 37888805). Equivalence should not be assumed for unstable, high-risk, digitally excluded, or poorly assessed patients.

Model Advantages Failure modes
Center-based Supervision, equipment, peer contact Travel, scheduling, work/care burden
Home-based Reach, convenience, contextual practice Isolation, device/connectivity barriers
Hybrid Tailored supervision and scale Fragmented data and handoffs
Community/task-shifted Lower cost and local access Variable integration with cardiology

Qualitative studies identify transport, work, cost, low perceived need, fear of exercise, family roles, and communication gaps as recurring barriers; contexts differ, so local co-design is required (Borah 2023, PMID 37033594; Xie 2022, PMID 36447215).

Exercise prescription

Exercise is prescribed after clinical assessment, not by a universal intensity. Aerobic volume, resistance work, progression, symptom thresholds, comorbidities, and recovery from sternotomy/MI shape the program.

Domain Practical measurement
Frequency Sessions/week
Intensity HR reserve, workload, RPE, talk test
Time Minutes/session and weekly total
Type Walking/cycling, intervals, resistance, balance
Progression Workload or duration change over time
Safety Angina, arrhythmia, hypotension, abnormal dyspnea

High-intensity interval and resistance training can improve outcomes in selected older adults with coronary disease, but supervision, orthopedic constraints, and baseline fitness determine suitability (Deka 2022, PMID 34171293).

Smoking cessation

Smoking cessation rapidly reduces thrombotic and longer-term atherosclerotic risk. Reduction without cessation leaves substantial risk; meta-analysis across health outcomes shows that “smoking less” is not equivalent to stopping (Chang 2021, PMID 32803250).

Effective programs combine repeated clinician advice, behavioral support, pharmacotherapy when appropriate, and relapse follow-up. A single discharge instruction is not an intervention.

Diet

PREDIMED's corrected republication found fewer major cardiovascular events with Mediterranean diets supplemented by extra-virgin olive oil or nuts in high-risk primary-prevention participants (Estruch 2018, PMID 29897866). For established IHD, the defensible translation is a pattern rich in vegetables, fruit, legumes, whole grains, nuts, and unsaturated fats, with less processed meat, refined carbohydrate, and sodium—not a claim that one branded food prevents recurrent MI.

Dietary counseling should account for culture, food security, diabetes, kidney disease, weight goals, and medications. Supplements do not reproduce a food-pattern trial.

Weight and cardiometabolic therapy

SELECT enrolled people with overweight/obesity and established cardiovascular disease without diabetes. Semaglutide reduced MACE (6.5% vs 8.0%; HR 0.80), demonstrating that obesity treatment can become secondary cardiovascular prevention (Lincoff 2023, PMID 37952131).

This pharmacologic result complements rather than invalidates lifestyle care: exercise, strength, diet quality, medication tolerance, and maintenance remain distinct outcomes.

Adherence engineering

SECURE randomized older post-MI patients to usual care or a polypill containing aspirin, ramipril, and atorvastatin. MACE occurred in 9.5% versus 12.7% (HR 0.76), with better adherence (Castellano 2022, PMID 36018037).

Adherence control Mechanism
Fewer daily pills Reduces regimen complexity
90-day refills/synchronization Reduces pharmacy gaps
Explicit discharge reconciliation Prevents omissions and duplication
Early follow-up Detects adverse effects before abandonment
Cost assistance/generics Reduces financial nonadherence
Shared decisions Aligns treatment with priorities and tolerance

Polypills constrain dose flexibility and do not fit contraindications equally; the relevant insight is that delivery design is causal.

Psychological recovery

Depression, anxiety, post-traumatic stress, and fear of exertion are common after MI. Psychological interventions produce modest improvements in psychological outcomes and may affect cardiac outcomes, but intervention content and trial quality vary (Richards 2018, PMID 29212370; Chong 2025, PMID 40142595).

Kinesiophobia can prevent return to safe activity; qualitative work documents a need for clearer individualized explanations of symptoms and exercise safety (Bäck 2020, PMID 32886775).

Implementation scorecard

Funnel stage Numerator Denominator Failure signal
Eligibility Assessed discharges All IHD discharges Unassessed groups
Referral Referred Eligible Clinician/system omission
Contact Contacted within 7–14 d Referred Handoff delay
Enrollment First session completed Contacted Access/acceptability barrier
Completion Program threshold reached Enrolled Retention failure
Maintenance Active at 6–12 mo Completed Transition failure
Clinical response Capacity/QoL/risk-factor improvement Participants with baseline data Ineffective dose or measurement loss

Reporting only referrals can hide failure at every later stage. The outcome evidence belongs to programs actually delivered, so implementation evaluation must preserve exposure and completion (Dibben 2023, PMID 36746187).

Evidence heterogeneity behind the pooled benefit

Evidence layer Finding Interpretation
Contemporary meta-analysis Exercise-based CR reduced cardiovascular mortality and hospitalization across randomized CHD trials (Dibben 2023, PMID 36746187). Programs, background therapy, diagnoses, and follow-up vary; “CR” is not one reproducible dose.
Earlier synthesis Programs reduced cardiovascular mortality and admissions but not clearly total mortality in all analyses (Anderson 2016, PMID 26764059). Improved acute care and prevention lower modern absolute benefit.
Updated Cochrane review Benefit persists across a broad evidence base, with important heterogeneity and bias limitations (Dibben 2021, PMID 34741536). Efficacy among attendees is not population effectiveness.
Pragmatic dissent RAMIT did not show the large mortality effect anticipated from older pooled trials (Doherty 2012, PMID 22505460). The neutral pragmatic result challenges assumptions about fidelity and contemporary absolute effect.
Delivery mode Home and center models are broadly comparable in selected patients (McDonagh 2023, PMID 37888805); telerehabilitation improves functional/risk-factor outcomes (Ramachandran 2022, PMID 34254118). Digital access, selection, adherence, and emergency support determine transportability.
Psychological care Programs improve some distress outcomes, while cardiac-event effects are inconsistent (Richards 2018, PMID 29212370; ENRICHD analysis, PMID 16617220). Mental health is patient-important but not a mortality surrogate.
Smoking Secondary-prevention evidence supports cessation; cigarette reduction leaves substantial risk (Wu 2022, PMID 35938889; Chang 2021, PMID 32803250). Verification and relapse materially affect estimates.
Diet Mediterranean-pattern evidence supports lower cardiovascular risk, but strongest randomized data are predominantly primary prevention (Estruch 2018, PMID 29897866; Rees 2019, PMID 30864165). Do not relabel primary-prevention evidence as post-MI evidence.

A US meta-analysis found CR attenders were younger than non-attenders (mean difference −3.74 years, 95% CI −5.87 to −1.61) and that participation odds were lower for women (OR 0.59, 95% CI 0.51–0.69), people with a high-school education or less (OR 0.67, 95% CI 0.50–0.91), and the uninsured or self-paying (OR 0.32, 95% CI 0.14–0.71) (Sun 2017, PMID 27676464). Studies in China and India identify distance, cost, work/care duties, risk perception, and weak referral as interacting barriers (Xie 2022, PMID 36447215; Borah 2023, PMID 37033594). Kinesiophobia can restrict activity after MI even when exercise is physiologically safe (Bäck 2020, PMID 32886775), while depression, anxiety, and PTSD warrant deliberate screening and referral (Chong 2025, PMID 40142595; Levine 2025, PMID 40977387).

The controversy is not center versus home in the abstract, but whether automatic referral, early contact, transport/digital support, culturally appropriate delivery, and stepped psychological care raise completed therapeutic dose without excluding high-risk patients. Trials should separately report referral, enrollment, sessions completed, exercise dose, medication attainment, smoking abstinence, function, hospitalization, mortality, adverse events, and subgroup reach.

Lifestyle care also interacts with pharmacologic implementation. SECURE showed that a post-MI polypill reduced MACE while simplifying adherence (Castellano 2022, PMID 36018037). SELECT found semaglutide reduced cardiovascular events in people with overweight/obesity and established CVD without diabetes (Lincoff 2023, PMID 37952131), but an injectable outcome drug is not a substitute for exercise, nutrition, smoking cessation, and rehabilitation. Higher-intensity interval/resistance programs can improve functional outcomes in selected older adults with coronary disease, although small studies cannot settle event safety or broad eligibility (Deka 2022, PMID 34171293). Genetic susceptibility does not negate lifestyle association: healthy lifestyle correlated with lower coronary risk across polygenic strata (Khera 2016, PMID 27959714).

Prevention guidance treats physical activity, tobacco, diet, psychosocial health, and adherence as integrated rather than optional domains (Visseren 2021, PMID 34458905; Virani 2023, PMID 37471501). Depression and anxiety also co-occur with subsequent MI/stroke risk in pooled observational evidence, although confounding and reverse causation prevent a simple causal treatment claim (Aw 2023, PMID 36610338).

Dose, delivery, and older evidence boundaries

Automatic referral can move the access denominator: in an Ontario cohort using an automatic system, 73.2% of survey respondents attended a CR assessment, and enrollment depended more on logistical barriers and illness perceptions than demographics (Grace 2004, PMID 15213491). This is observational and subject to survey response, but it demonstrates why referral design and treatment efficacy are different causal questions.

The secondary-prevention effect sizes behind lifestyle counseling are not interchangeable in evidentiary strength. A meta-analysis of 12 cohorts (5,878 post-MI patients) associated smoking cessation with mortality OR 0.54 (95% CI 0.46–0.62), estimated NNT 13 under an assumed 20% mortality rate in continuing smokers (Wilson 2000, PMID 10761958). The randomized Lyon Diet Heart Study reported cardiac death/nonfatal MI in 14 Mediterranean-pattern versus 44 comparison participants over mean 46 months, with adjusted risk ratios across broader composites of 0.28–0.53; its era, small event counts, and dietary-comparator complexity limit direct translation to contemporary care (de Lorgeril 1999, PMID 9989963).

Exercise dose has more contemporary randomized data. In 382 stable-CAD CR participants, twice-weekly low-volume high-intensity intervals improved peak oxygen uptake 1.04 mL/kg/min more than moderate continuous training (95% CI 0.38–1.69) at 8 weeks, with one possibly related serious adverse event (McGregor 2023, PMID 36753063). That supports an assessed alternative within CR, not unsupervised high-intensity exercise for every post-ACS patient.

Open questions

  • Which automatic-referral and enrollment model yields the largest absolute increase in completed CR across sex, age, rurality, and income groups?
  • Can home/hybrid CR reproduce trial outcomes in digitally excluded and higher-risk patients? (McDonagh 2023, PMID 37888805)
  • What is the minimum effective CR “dose,” and which components drive mortality versus quality-of-life effects? (Dibben 2023, PMID 36746187)
  • Can polypill and CR delivery be combined without losing dose individualization? (Castellano 2022, PMID 36018037)
  • How should obesity pharmacotherapy, exercise, and muscle-preservation programs be integrated after MI? (Lincoff 2023, PMID 37952131)

References

  1. Dibben GO, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44:452-469. PMID 36746187
  2. McDonagh ST, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023;10:CD007130. PMID 37888805
  3. Chang JT, et al. Cigarette Smoking Reduction and Health Risks: A Systematic Review and Meta-analysis. Nicotine Tob Res. 2021;23:635-642. PMID 32803250
  4. Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378:e34. PMID 29897866
  5. Castellano JM, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387:967-977. PMID 36018037
  6. Dibben G, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11:CD001800. PMID 34741536
  7. Anderson L, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016;67:1-12. PMID 26764059
  8. Borah N, et al. Challenges to Cardiac Rehabilitation Post Coronary Artery Bypass Grafting: A Qualitative Study in Pune. Cureus. 2023;15:e35755. PMID 37033594
  9. Xie X, et al. Barriers to hospital-based phase 2 cardiac rehabilitation among patients with coronary heart disease in China: a mixed-methods study. BMC Nurs. 2022;21:333. PMID 36447215
  10. Deka P, et al. High-Intensity Interval and Resistance Training Improve Health Outcomes in Older Adults With Coronary Disease. J Am Med Dir Assoc. 2022;23:60-65. PMID 34171293
  11. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. PMID 37952131
  12. Richards SH, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:247-259. PMID 29212370
  13. Chong RJ, et al. Prevalence of Depression, Anxiety and Post-Traumatic Stress Disorder (PTSD) After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14:1786. PMID 40142595
  14. Bäck M, et al. Perceptions of Kinesiophobia in Relation to Physical Activity and Exercise After Myocardial Infarction: A Qualitative Study. Phys Ther. 2020;100:2110-2119. PMID 32886775
  15. Doherty P, et al. The RAMIT trial, a pragmatic RCT of cardiac rehabilitation versus usual care: what does it tell us? Heart. 2012;98:605-6. PMID 22505460
  16. Ramachandran HJ, et al. Effectiveness of home-based cardiac telerehabilitation as an alternative to Phase 2 cardiac rehabilitation of coronary heart disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:1017-1043. PMID 34254118
  17. Mendes de Leon CF, et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial. J Cardiopulm Rehabil. 2006;26:9-13; quiz 14-5. PMID 16617220
  18. Wu AD, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022;8:CD014936. PMID 35938889
  19. Rees K, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019;3:CD009825. PMID 30864165
  20. Sun EY, et al. Disparities in Cardiac Rehabilitation Participation in the United States: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2017;37:2-10. PMID 27676464
  21. Levine GN, et al. Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association. Circulation. 2025;152:e298-e310. PMID 40977387
  22. Khera AV, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375:2349-2358. PMID 27959714
  23. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. PMID 34458905
  24. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501
  25. Aw PY, et al. Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysis. J Psychosom Res. 2023;165:111141. PMID 36610338
  26. Grace SL, et al. Automatic referral to cardiac rehabilitation. Med Care. 2004;42:661-669. PMID 15213491
  27. Wilson K, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000;160:939-944. PMID 10761958
  28. de Lorgeril M, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779-785. PMID 9989963
  29. McGregor G, et al. High-intensity interval training in cardiac rehabilitation: a multi-centre randomized controlled trial. Eur J Prev Cardiol. 2023;30:745-755. PMID 36753063